Items Tagged ‘docetaxel’

November 10, 2015

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer


Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung cancer (NSCLC). These results were recently published in the New England Journal of Medicine while simultaneously being presented at the 2015 European Cancer Congress. Lung cancer remains […]

View full entry

Tags: advanced, docetaxel, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-squamous, nsclc, opdivo, PD-1 inhibitor, Recurrent Lung Cancer - Non-Small Cell, squamous

June 3, 2014

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients


In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend overall survival by more than 13 months. The results were reported at the 2014 American Society of Clinical Oncology (ASCO) meeting held in Chicago. Prostate cancer occurs when the […]

View full entry

Tags: asco, docetaxel, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, taxotere